US startup Clair Health has raised $11.6M for a wearable that continuously tracks women’s hormones without blood draws. The jewellery-inspired device uses 10 biosensors and more than 130 biomarkers to read estrogen, progesterone, LH and FSH — from menstruation through menopause. The round was led by Khosla Ventures, with backers including Anne Wojcicki. The device launches in November at $369 plus a monthly subscription, and its first run of 5,000 units sold out six months before release. Clair plans a clinical trial through Stanford to validate the technology.
Where sleep and heart rate have long been measurable, the continuous hormone ledger now moves in as the next stream of data. The body’s most private cycle becomes a number you can subscribe to.
So…:
What would your customers optimise if they could measure it all the time?
Source:
Picture:
Clair Health (press)